Jo Appleyard - Ryman Healthcare Independent Non-Executive Director
RYHTY Stock | USD 13.65 0.16 1.19% |
Director
Ms. Jo Appleyard is NonExecutive Independent Director of Ryman Healthcare Ltd. Jo is a partner at Chapman Tripp. She is a skilled advocate and litigator specialising in commercial, employment, and resource management law. Jo was a member of the NZ Markets Disciplinary Tribunal since 2011. since 2009.
Tenure | 15 years |
Phone | 64 3 366 4069 |
Web | https://www.rymanhealthcare.co.nz |
Ryman Healthcare Management Efficiency
Ryman Healthcare's management efficiency ratios could be used to measure how well Ryman Healthcare manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Donald Wilson | Barloworld Ltd ADR | 59 | |
Peter Eckert | SCOR PK | 70 | |
Babalwa Ngonyama | Barloworld Ltd ADR | 40 | |
Peter Schmid | Barloworld Ltd ADR | 53 | |
Kory Sorenson | SCOR PK | 49 | |
Michele Aronvald | SCOR PK | 57 | |
Bruno Pfister | SCOR PK | 59 | |
John DePodesta | Gen Digital | 74 | |
Wang Zhen | SCOR PK | 61 | |
Sibongile Mkhabela | Barloworld Ltd ADR | 60 | |
JeanMarc Raby | SCOR PK | 59 | |
Maria Singer | Universal Health Services | 46 | |
Jane WickerMiurin | SCOR PK | 59 | |
Joshua Hausman | Gen Digital | N/A | |
Warren Nimetz | Universal Health Services | 64 | |
Kevin Knoer | SCOR PK | 58 | |
Hester Hickey | Barloworld Ltd ADR | 62 | |
Augustin Romanet | SCOR PK | 55 | |
Ngozichukwuka Edozien | Barloworld Ltd ADR | 48 | |
Neo Dongwana | Barloworld Ltd ADR | 44 | |
David Reis | Gen Digital | 56 |
Management Performance
Return On Equity | 0.18 | |||
Return On Asset | -7.0E-4 |
Ryman Healthcare Leadership Team
Elected by the shareholders, the Ryman Healthcare's board of directors comprises two types of representatives: Ryman Healthcare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ryman. The board's role is to monitor Ryman Healthcare's management team and ensure that shareholders' interests are well served. Ryman Healthcare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ryman Healthcare's outside directors are responsible for providing unbiased perspectives on the board's policies.
Claire Higgins, Non-Executive Independent Director | ||
Anthony Leighs, Independent Director | ||
Cameron Holland, Chief Australia | ||
Richard Umbers, Group Exec | ||
Gordon MacLeod, CFO, Deputy Chief Executive and Company Secretary | ||
Kevin Hickman, Co-Founder, Director and Member of Remuneration and Nominations Committee | ||
Taylor Allison, Design Manager | ||
Michelle Perkins, IR Contact Officer | ||
Simon Challies, CEO, Managing Director, Executive Director | ||
Tom Brownrigg, Construction Manager | ||
Jo Appleyard, Independent Non-Executive Director | ||
Jenn Poskitt, Marketing Manager | ||
Philip Mealings, Property and Purchasing Manager | ||
George Savvides, Independent Director | ||
Douglas McKay, Independent Director | ||
Cheyne Chalmers, Chief Zealand | ||
Debbie McClure, Group Sales Manager | ||
Warren Bell, Independent Non-Executive Director | ||
David Bennett, Group Officer | ||
Deborah Marris, G Sec | ||
Marsha Cadman, Chief Officer | ||
Rick Davies, Chief Officer | ||
Andrew Mitchell, Development Manager | ||
David Kerr, Independent Non-Executive Chairman of the Board | ||
Geoffrey Cumming, Director | ||
MaryAnne Stone, Chief Officer | ||
David King, Corporate Affairs Manager | ||
Chris BE, Chief Officer | ||
Barbara ReynenRose, Operations & Clinical Services Manager | ||
Nicole Forster, Group Shared Services Manager |
Ryman Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Ryman Healthcare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.18 | |||
Return On Asset | -7.0E-4 | |||
Profit Margin | 1.13 % | |||
Operating Margin | (0.02) % | |||
Current Valuation | 3.91 B | |||
Shares Outstanding | 100 M | |||
Price To Earning | 10.13 X | |||
Price To Book | 0.85 X | |||
Price To Sales | 3.74 X | |||
Revenue | 503.76 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Ryman Healthcare in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Ryman Healthcare's short interest history, or implied volatility extrapolated from Ryman Healthcare options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ryman Healthcare. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Ryman Pink Sheet analysis
When running Ryman Healthcare's price analysis, check to measure Ryman Healthcare's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ryman Healthcare is operating at the current time. Most of Ryman Healthcare's value examination focuses on studying past and present price action to predict the probability of Ryman Healthcare's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ryman Healthcare's price. Additionally, you may evaluate how the addition of Ryman Healthcare to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |